Salvage surgery after chemoradiotherapy in the management of esophageal cancer
Purpose: The aim of this large multicenter study was to assess the impact of salvage esophagectomy after definitive chemoradiotherapy (SALV) on clinical outcome. Patients and methods: Data from consecutive adult patients undergoing resection for esophageal cancer in 30 European centers from 2000 to...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , |
| التنسيق: | article |
| منشور في: |
2015
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/14212 https://doi.org/10.1200/JCO.2014.59.9092 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://pubmed.ncbi.nlm.nih.gov/26195702/ |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513469199417344 |
|---|---|
| author | Markar, Sheraz |
| author2 | Gronnier, Caroline Duhamel, Alain Pasquer, Arnaud Théreaux, Jérémie Du Rieu, Mael Chalret Lefevre, Jérémie H. Turner, Kathleen Luc, Guillaume Mariette, Christophe |
| author2_role | author author author author author author author author author |
| author_facet | Markar, Sheraz Gronnier, Caroline Duhamel, Alain Pasquer, Arnaud Théreaux, Jérémie Du Rieu, Mael Chalret Lefevre, Jérémie H. Turner, Kathleen Luc, Guillaume Mariette, Christophe |
| author_role | author |
| dc.contributor.none.fl_str_mv | Chemaly, Rodrigue |
| dc.creator.none.fl_str_mv | Markar, Sheraz Gronnier, Caroline Duhamel, Alain Pasquer, Arnaud Théreaux, Jérémie Du Rieu, Mael Chalret Lefevre, Jérémie H. Turner, Kathleen Luc, Guillaume Mariette, Christophe |
| dc.date.none.fl_str_mv | 2015 2022-11-03T14:22:20Z 2022-11-03T14:22:20Z 2022-11-03 |
| dc.identifier.none.fl_str_mv | 0732-183X http://hdl.handle.net/10725/14212 https://doi.org/10.1200/JCO.2014.59.9092 Markar, S., Gronnier, C., Duhamel, A., Pasquer, A., Théreaux, J., du Rieu, M. C., ... & Mariette, C. (2015). Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 33(33), 3866-3873. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://pubmed.ncbi.nlm.nih.gov/26195702/ |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Journal of Clinical Oncology (JCO) |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Salvage surgery after chemoradiotherapy in the management of esophageal cancer is it a viable therapeutic option? |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Purpose: The aim of this large multicenter study was to assess the impact of salvage esophagectomy after definitive chemoradiotherapy (SALV) on clinical outcome. Patients and methods: Data from consecutive adult patients undergoing resection for esophageal cancer in 30 European centers from 2000 to 2010 were collected. First, groups undergoing SALV (n = 308) and neoadjuvant chemoradiotherapy followed by planned esophagectomy (NCRS; n = 540) were compared. Second, patients who benefited from SALV for persistent (n = 234) versus recurrent disease (n = 74) were compared. Propensity score matching and multivariable analyses were used to compensate for differences in some baseline characteristics. Results: SALV versus NCRS groups: In-hospital mortality was similar in both groups (8.4% v 9.3%). The only significant differences in complications were seen for anastomotic leak (17.2% v 10.7%; P = .007) and surgical site infection, which were both more frequent in the SALV group. At 3 years, groups had similar overall (43.3% v 40.1%; P = .542) and disease-free survival (39.2% v 32.8%; P = .232) after matching, along with a similar recurrence pattern. Persistent versus recurrent disease groups: There were no significant differences between groups in incidence of in-hospital mortality or major complications. At 3 years, overall (40.9% v 56.2%; P = .046) and disease-free survival (36.6% v 51.6%; P = .095) were lower in the persistent disease group. Conclusion: The results of this large multicenter study from the modern era suggest that SALV can offer acceptable short- and long-term outcomes in selected patients at experienced centers. Persistent cancer after definitive chemoradiotherapy seems to be more biologically aggressive, with poorer survival compared with recurrent cancer. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_9e9f2daba1100bef295683f54b42e6bb |
| identifier_str_mv | 0732-183X Markar, S., Gronnier, C., Duhamel, A., Pasquer, A., Théreaux, J., du Rieu, M. C., ... & Mariette, C. (2015). Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 33(33), 3866-3873. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/14212 |
| publishDate | 2015 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Salvage surgery after chemoradiotherapy in the management of esophageal canceris it a viable therapeutic option?Markar, SherazGronnier, CarolineDuhamel, AlainPasquer, ArnaudThéreaux, JérémieDu Rieu, Mael ChalretLefevre, Jérémie H.Turner, KathleenLuc, GuillaumeMariette, ChristophePurpose: The aim of this large multicenter study was to assess the impact of salvage esophagectomy after definitive chemoradiotherapy (SALV) on clinical outcome. Patients and methods: Data from consecutive adult patients undergoing resection for esophageal cancer in 30 European centers from 2000 to 2010 were collected. First, groups undergoing SALV (n = 308) and neoadjuvant chemoradiotherapy followed by planned esophagectomy (NCRS; n = 540) were compared. Second, patients who benefited from SALV for persistent (n = 234) versus recurrent disease (n = 74) were compared. Propensity score matching and multivariable analyses were used to compensate for differences in some baseline characteristics. Results: SALV versus NCRS groups: In-hospital mortality was similar in both groups (8.4% v 9.3%). The only significant differences in complications were seen for anastomotic leak (17.2% v 10.7%; P = .007) and surgical site infection, which were both more frequent in the SALV group. At 3 years, groups had similar overall (43.3% v 40.1%; P = .542) and disease-free survival (39.2% v 32.8%; P = .232) after matching, along with a similar recurrence pattern. Persistent versus recurrent disease groups: There were no significant differences between groups in incidence of in-hospital mortality or major complications. At 3 years, overall (40.9% v 56.2%; P = .046) and disease-free survival (36.6% v 51.6%; P = .095) were lower in the persistent disease group. Conclusion: The results of this large multicenter study from the modern era suggest that SALV can offer acceptable short- and long-term outcomes in selected patients at experienced centers. Persistent cancer after definitive chemoradiotherapy seems to be more biologically aggressive, with poorer survival compared with recurrent cancer.PublishedChemaly, Rodrigue2022-11-03T14:22:20Z2022-11-03T14:22:20Z20152022-11-03Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article0732-183Xhttp://hdl.handle.net/10725/14212https://doi.org/10.1200/JCO.2014.59.9092Markar, S., Gronnier, C., Duhamel, A., Pasquer, A., Théreaux, J., du Rieu, M. C., ... & Mariette, C. (2015). Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 33(33), 3866-3873.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://pubmed.ncbi.nlm.nih.gov/26195702/enJournal of Clinical Oncology (JCO)info:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/142122022-11-03T14:22:20Z |
| spellingShingle | Salvage surgery after chemoradiotherapy in the management of esophageal cancer Markar, Sheraz |
| status_str | publishedVersion |
| title | Salvage surgery after chemoradiotherapy in the management of esophageal cancer |
| title_full | Salvage surgery after chemoradiotherapy in the management of esophageal cancer |
| title_fullStr | Salvage surgery after chemoradiotherapy in the management of esophageal cancer |
| title_full_unstemmed | Salvage surgery after chemoradiotherapy in the management of esophageal cancer |
| title_short | Salvage surgery after chemoradiotherapy in the management of esophageal cancer |
| title_sort | Salvage surgery after chemoradiotherapy in the management of esophageal cancer |
| url | http://hdl.handle.net/10725/14212 https://doi.org/10.1200/JCO.2014.59.9092 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://pubmed.ncbi.nlm.nih.gov/26195702/ |